Entero Healthcare Solutions Limited , a leading healthcare supply chain company, has reported strong financial results for the second quarter of fiscal year 2026, along with significant strategic moves to expand its MedTech operations.

Financial Highlights

For Q2FY26, Entero Healthcare reported consolidated revenue of Rs. 15,709.48 crore, marking a robust 21% year-on-year growth. The company achieved an EBITDA of Rs. 621.00 crore, representing a 4% margin, and a Profit After Tax (PAT) of Rs. 366.00 crore, translating to a 2.3% PAT margin.

Key financial metrics for Q2FY26 include:

The company's performance shows significant improvement in profitability, with EBITDA and PAT growth outpacing revenue growth.

Strategic Acquisitions in MedTech Segment

Entero Healthcare announced two margin-accretive acquisitions in the MedTech segment:

1. Bioaide Technologies Private Limited: The company plans to acquire an 80% stake for Rs. 31.13-36.00 crore.
2. Anand Chemiceutics Private Limited: A binding MoU has been signed to acquire a 51% stake for Rs. 210.00-230.00 crore.

These acquisitions are expected to generate Rs. 1,000.00 crore in annualized revenue and improve the company's gross margins by 70-90 basis points and EBITDA margins by 50-75 basis points.

Operational Highlights

• Customer base expanded to 85,300+ retail pharmacies and 2,800+ hospitals.
• Relationships with 2,800+ healthcare product manufacturers.
• Presence in 20 states, 47 cities, and 490 districts across India.
• 113 warehouses with a total area of 610,169 sq ft.

Management Commentary

Prabhat Agrawal, Promoter, Managing Director and CEO, stated, "The quarter reflects continuation of strong growth trajectory and margin expansion. We achieved an EBITDA Margin of 4% through focus on gross margin expansion along with improvement in net working capital days. As we complete the first half of the year, we remain on-track to deliver on our full-year guidance."

He added, "We are expanding significantly in the MedTech segment through new acquisitions which marked a pivotal step forward- a move that creates meaningful synergies with our existing pharmaceutical distribution and enhances our overall margin profile."

Future Outlook

With stronger momentum and visibility in the second half of the financial year, Entero Healthcare is well-positioned to accelerate growth, deliver margin improvement, and generate operating cash flow. The strategic acquisitions in the MedTech segment are expected to complement the company's existing operations and contribute to its long-term growth strategy.

Investors and analysts will be watching closely to see how these acquisitions integrate with Entero's existing business and contribute to the company's financial performance in the coming quarters.

Entero Healthcare Solutions Limited , a leading player in the healthcare supply chain sector, has announced several significant corporate updates, including a key executive promotion and strategic acquisitions to bolster its market position.

Executive Promotion

The company's Board of Directors has approved the promotion of Abhitesh Kumar from President - Retail Business & New Initiatives to Chief Growth Officer. Kumar, who holds a B.Tech in Mechanical Engineering from BITS Pilani and a Post Graduate program in Business Management from IIM Calcutta, brings over a decade of experience to his new role, including nine years in the pharmaceutical industry.

Entero Healthcare stated that Kumar has been instrumental in scaling the company's retail business since its inception. This elevation is expected to further accelerate Entero's growth trajectory.

Strategic Acquisitions

In a move to expand its market presence, Entero Healthcare has announced two significant acquisitions:

1. Bioaide Technologies Private Limited: The company has entered into definitive agreements to acquire an 80% stake in Bioaide Technologies. The acquisition, valued between INR 31.13 Crore to INR 36 Crore, is expected to be completed by February 15, 2026. Bioaide, incorporated in 1996, specializes in the wholesale distribution of medical devices and other healthcare products.

2. Anand Chemiceutics Private Limited: Entero has signed a binding Memorandum of Understanding to acquire a 51% stake in Anand Chemiceutics. This acquisition, ranging between INR 210 Crore to INR 230 Crore, is subject to due diligence and execution of definitive agreements. Anand Chemiceutics, incorporated in 2022, focuses on wholesale distribution of medical devices and turnkey projects in healthcare institutions.

Financial Performance

Entero Healthcare also released its unaudited consolidated financial results:

All figures in INR million

Employee Stock Options

The company has allotted 2,030 equity shares under its Employee Stock Option Plan 2023, increasing its total paid-up equity share capital to INR 43,51,09,370.

These developments underscore Entero Healthcare's commitment to growth and expansion in the healthcare distribution sector. The strategic acquisitions are expected to strengthen the company's market position, while the executive promotion signals a focus on driving future growth initiatives.